Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 933 (107th)

Affordable HIV/AIDS Medicines for Poor Countries Act

referredUnited States· United States Congress· EN

Introduced

7 March 2001

Last action

14 March 2001 · Referred

Status

Referred to the Subcommittee on Trade.

Sponsors

Rep. Waters, Maxine [D-CA-43], Del. Christensen, Donna M. [D-VI-At Large], Rep. Schakowsky, Janice D. [D-IL-9], Rep. Lee, Barbara [D-CA-12], Rep. Frank, Barney [D-MA-4], Sen. Brown, Sherrod [D-OH], Rep. Pelosi, Nancy [D-CA-11], Rep. Jackson Lee, Sheila [D-TX-18], Rep. Conyers, John, Jr. [D-MI-13], Sen. Sanders, Bernard [I-VT], Rep. Abercrombie, Neil [D-HI-1], Rep. Serrano, Jose E. [D-NY-15], Rep. Wynn, Albert Russell [D-MD-4], Rep. Nadler, Jerrold [D-NY-12], Rep. Frost, Martin [D-TX-24], Rep. Jackson, Jesse L., Jr. [D-IL-2], Rep. Payne, Donald M. [D-NJ-10], Rep. Hilliard, Earl F. [D-AL-7], Rep. McCollum, Betty [D-MN-4], Rep. Towns, Edolphus [D-NY-10], Rep. Jones, Stephanie Tubbs [D-OH-11], Rep. Mink, Patsy T. [D-HI-2], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Rush, Bobby L. [D-IL-1], Rep. Rangel, Charles B. [D-NY-15], Rep. Kucinich, Dennis J. [D-OH-10], Rep. Evans, Lane [D-IL-17], Rep. Kildee, Dale E. [D-MI-5], Rep. Woolsey, Lynn C. [D-CA-6], Rep. Harman, Jane [D-CA-36], Rep. Filner, Bob [D-CA-51], Rep. Allen, Thomas H. [D-ME-1], Rep. Gutierrez, Luis V. [D-IL-4], Rep. McKinney, Cynthia A. [D-GA-4], Rep. Cummings, Elijah E. [D-MD-7], Rep. Gonzalez, Charles A. [D-TX-20], Rep. Lantos, Tom [D-CA-12], Rep. Miller, George [D-CA-11], Rep. Carson, Julia [D-IN-7], Rep. Jefferson, William J. [D-LA-2], Rep. Clyburn, James E. [D-SC-6], Rep. Owens, Major R. [D-NY-11], Rep. Clay, Wm. Lacy [D-MO-1], Rep. Bishop, Sanford D. [D-GA-2], Rep. Brown, Corrine [D-FL-5], Rep. Clayton, Eva M. [D-NC-1], Rep. Andrews, Robert E. [D-NJ-1], Rep. Farr, Sam [D-CA-20]

Subjects

Discovery layer

Source updated

19 August 2025

Summary

Affordable HIV/AIDS Medicines for Poor Countries Act - Directs the Secretary of the Treasury, the Administrator of the U.S. Agency for International Development, and the U.S. Trade Representative (USTR) to encourage developing countries (including sub-Saharan African countries) and pharmaceutical companies to make HIV/AIDS pharmaceuticals and medical technologies available to people who live in such countries without charge or at affordable prices. Sets forth certain restrictions and limitations, including that: (1) appropriated funds made available to U.S. agencies may not be obligated to seek the revocation or revision of any intellectual property or competition law or policy of a developing country (including any sub- Saharan African country) that regulates HIV/AIDS pharmaceuticals or medical technologies if such law or policy promotes access to such drugs and technologies by the country's population; and (2) the USTR may not initiate a proceeding in the World Trade Organization (WTO) challenging any law or policy of a developing country (including a sub-Saharan African country) that promotes access by HIV/AIDS pharmaceuticals or medical technologies by the population of the country. Requires the President to direct the U.S. representative to the WTO to urge the WTO and member countries to exempt developing countries (including sub-Saharan African countries) from the application of any provision of the Agreement on Trade-Related Aspects of Intellectual Property Rights or any other international agreement relating to intellectual property rights that would prohibit or restrict such countries from establishing or implementing any law or policy that promotes access to HIV/AIDS pharmaceuticals or medical technologies to their population.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 7 March 2001

    Introduced

    Referred to the Committee on Ways and Means, and in addition to the Committee on International Relations, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  2. 7 March 2001

    Introduced

    Referred to the Committee on Ways and Means, and in addition to the Committee on International Relations, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  3. 7 March 2001

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 7 March 2001

    Introduced

    Introduced in House

    Source: IntroReferral

  5. 14 March 2001

    Referred

    Referred to the Subcommittee on Trade.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 7 March 2001

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 7 March 2001

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 7 March 2001

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 67 sponsors and actors.

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.